BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24889916)

  • 1. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).
    Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI
    Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study.
    Baldwin RL; Nemeth E; Tran H; Shvartsman H; Cass I; Narod S; Karlan BY
    Cancer Res; 2000 Oct; 60(19):5329-33. PubMed ID: 11034065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Versus Epigenetic BRCA1 Silencing Pathways: Clinical Effects in Primary Ovarian Cancer Patients: A Study of the Tumor Bank Ovarian Cancer Consortium.
    Sun T; Ruscito I; Dimitrova D; Chekerov R; Kulbe H; Baron U; Blanchard V; Panici PB; Darb-Esfahani S; Sehouli J; Olek S; Braicu EI
    Int J Gynecol Cancer; 2017 Oct; 27(8):1658-1665. PubMed ID: 28691938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk.
    Lønning PE; Berge EO; Bjørnslett M; Minsaas L; Chrisanthar R; Høberg-Vetti H; Dulary C; Busato F; Bjørneklett S; Eriksen C; Kopperud R; Axcrona U; Davidson B; Bjørge L; Evans G; Howell A; Salvesen HB; Janszky I; Hveem K; Romundstad PR; Vatten LJ; Tost J; Dørum A; Knappskog S
    Ann Intern Med; 2018 Mar; 168(5):326-334. PubMed ID: 29335712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
    Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
    J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
    Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.
    Montavon C; Gloss BS; Warton K; Barton CA; Statham AL; Scurry JP; Tabor B; Nguyen TV; Qu W; Samimi G; Hacker NF; Sutherland RL; Clark SJ; O'Brien PM
    Gynecol Oncol; 2012 Mar; 124(3):582-8. PubMed ID: 22115852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
    Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
    J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.
    Wilcox CB; Baysal BE; Gallion HH; Strange MA; DeLoia JA
    Cancer Genet Cytogenet; 2005 Jun; 159(2):114-22. PubMed ID: 15899382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 promoter hypermethylation and protein expression in ovarian carcinoma--an Indian study.
    Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L
    Tumour Biol; 2014 May; 35(5):4277-84. PubMed ID: 24385383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
    Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
    Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
    Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
    Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
    Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
    Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline mutations of BRCA1 gene exon 11 are not associated with platinum response neither with survival advantage in patients with primary ovarian cancer: understanding the clinical importance of one of the biggest human exons. A study of the Tumor Bank Ovarian Cancer (TOC) Consortium.
    Dimitrova D; Ruscito I; Olek S; Richter R; Hellwag A; Türbachova I; Woopen H; Baron U; Braicu EI; Sehouli J
    Tumour Biol; 2016 Sep; 37(9):12329-12337. PubMed ID: 27297669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of allelic loss at the BRCA1 locus in ovarian cancers: clinicopathologic and molecular associations.
    Rzepecka IK; Szafron L; Stys A; Bujko M; Plisiecka-Halasa J; Madry R; Osuch B; Markowska J; Bidzinski M; Kupryjanczyk J
    Cancer Genet; 2012 Mar; 205(3):94-100. PubMed ID: 22469508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
    Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
    Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and p53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriers.
    Kontorovich T; Cohen Y; Nir U; Friedman E
    Breast Cancer Res Treat; 2009 Jul; 116(1):195-200. PubMed ID: 18642075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
    Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
    Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer.
    Katsaros D; Cho W; Singal R; Fracchioli S; Rigault De La Longrais IA; Arisio R; Massobrio M; Smith M; Zheng W; Glass J; Yu H
    Gynecol Oncol; 2004 Sep; 94(3):685-92. PubMed ID: 15350359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.